Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance

7 Feb 2008

Abstract excerpt

UNLABELLED: Virologic resistance emerging during entecavir (ETV) therapy for hepatitis B virus (HBV) requires three substitutions in the viral reverse transcriptase (RT), signifying a high barrier to resistance. Two of these substitutions are associated with lamivudine resistance (LVDr) in the tyrosine-methionine-aspartate-aspartate (YMDD) motif (rtM204V and rtL180M), whereas the other occurs at one or more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug-Induced Hepatotoxicity and Protection
Share to Hepatitis B Virus Studies
Share to Hepatitis C virus research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18435459
DOI: 10.1002/hep.22211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistancePMID 18435459Read ↗

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.Semantic proximity Read ↗

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.Semantic proximity Read ↗

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.Semantic proximity Read ↗

Characterization of novel entecavir resistance mutations.Semantic proximity Read ↗

Successful treatment of an entecavir-resistant hepatitis B virus variant.Semantic proximity Read ↗

Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies.Semantic proximity Read ↗

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #Semantic proximity Read ↗

Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.Semantic proximity Read ↗

Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.Semantic proximity Read ↗

Antiviral drug resistance: clinical consequences and molecular aspects.Semantic proximity Read ↗

Entecavir resistance is rare in nucleoside naïve patients with hepatitis BSemantic proximity Read ↗

Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.